182 related articles for article (PubMed ID: 34474439)
21. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
22. Prognostic risk score for patients with relapsed or refractory chronic lymphocytic leukaemia treated with targeted therapies or chemoimmunotherapy: a retrospective, pooled cohort study with external validations.
Soumerai JD; Ni A; Darif M; Londhe A; Xing G; Mun Y; Kay NE; Shanafelt TD; Rabe KG; Byrd JC; Chanan-Khan AA; Furman RR; Hillmen P; Jones J; Seymour JF; Sharman JP; Ferrante L; Mobasher M; Stark T; Reddy V; Dreiling LK; Bhargava P; Howes A; James DF; Zelenetz AD
Lancet Haematol; 2019 Jul; 6(7):e366-e374. PubMed ID: 31109827
[TBL] [Abstract][Full Text] [Related]
23. Targeted therapies for CLL: Practical issues with the changing treatment paradigm.
Jain N; O'Brien S
Blood Rev; 2016 May; 30(3):233-44. PubMed ID: 26776345
[TBL] [Abstract][Full Text] [Related]
24. Frontline Therapy of CLL: Evolving Treatment Paradigm.
Boddy CS; Ma S
Curr Hematol Malig Rep; 2018 Apr; 13(2):69-77. PubMed ID: 29480432
[TBL] [Abstract][Full Text] [Related]
25. Low-dose fludarabine and cyclophosphamide combined with rituximab in the first-line treatment of elderly/comorbid patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL): long-term results of project Q-lite by the Czech CLL Study Group.
Smolej L; Brychtová Y; Cmunt E; Doubek M; Špaček M; Belada D; Šimkovič M; Stejskal L; Zygulová I; Urbanová R; Brejcha M; Zuchnická J; Móciková H; Kozák T;
Br J Haematol; 2021 May; 193(4):769-778. PubMed ID: 33618437
[TBL] [Abstract][Full Text] [Related]
26. Current and future treatment strategies in chronic lymphocytic leukemia.
Patel K; Pagel JM
J Hematol Oncol; 2021 Apr; 14(1):69. PubMed ID: 33902665
[TBL] [Abstract][Full Text] [Related]
27. Signal transduction inhibitors in chronic lymphocytic leukemia.
Ma S; Rosen ST
Curr Opin Oncol; 2011 Nov; 23(6):601-8. PubMed ID: 21892084
[TBL] [Abstract][Full Text] [Related]
28. Improving risk-stratification of patients with chronic lymphocytic leukemia using multivariate patient similarity networks.
Turcsanyi P; Kriegova E; Kudelka M; Radvansky M; Kruzova L; Urbanova R; Schneiderova P; Urbankova H; Papajik T
Leuk Res; 2019 Apr; 79():60-68. PubMed ID: 30852300
[TBL] [Abstract][Full Text] [Related]
29. Ofatumumab-based chemoimmunotherapy is effective and well tolerated in patients with previously untreated chronic lymphocytic leukemia (CLL).
Shanafelt T; Lanasa MC; Call TG; Beaven AW; Leis JF; LaPlant B; Bowen D; Conte M; Jelinek DF; Hanson CA; Kay NE; Zent CS
Cancer; 2013 Nov; 119(21):3788-96. PubMed ID: 23922059
[TBL] [Abstract][Full Text] [Related]
30. The Shifting Paradigm in Chronic Lymphocytic Leukemia: Is Chemotherapy Still Relevant?
Jain N; OʼBrien S
Cancer J; 2019; 25(6):374-377. PubMed ID: 31764117
[TBL] [Abstract][Full Text] [Related]
31. What Is Optimal Front-Line Therapy for Chronic Lymphocytic Leukemia in 2017?
Voorhies BN; Stephens DM
Curr Treat Options Oncol; 2017 Feb; 18(2):12. PubMed ID: 28243993
[TBL] [Abstract][Full Text] [Related]
32. Chronic lymphocytic leukemia and infection risk in the era of targeted therapies: Linking mechanisms with infections.
Hilal T; Gea-Banacloche JC; Leis JF
Blood Rev; 2018 Sep; 32(5):387-399. PubMed ID: 29571669
[TBL] [Abstract][Full Text] [Related]
33. The evolving treatment landscape of chronic lymphocytic leukemia.
Schiattone L; Ghia P; Scarfò L
Curr Opin Oncol; 2019 Nov; 31(6):568-573. PubMed ID: 31593975
[TBL] [Abstract][Full Text] [Related]
34. [Advances in the treatment of chronic lymphocytic leukaemia].
Mozas P; Delgado J
Med Clin (Barc); 2016 Nov; 147(10):447-454. PubMed ID: 27431885
[TBL] [Abstract][Full Text] [Related]
35. Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy.
Byrd JC; Gribben JG; Peterson BL; Grever MR; Lozanski G; Lucas DM; Lampson B; Larson RA; Caligiuri MA; Heerema NA
J Clin Oncol; 2006 Jan; 24(3):437-43. PubMed ID: 16344317
[TBL] [Abstract][Full Text] [Related]
36. Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations.
Jain N; Thompson P; Burger J; Ferrajoli A; Takahashi K; Estrov Z; Borthakur G; Bose P; Kadia T; Pemmaraju N; Sasaki K; Konopleva M; Jabbour E; Garg N; Wang X; Kanagal-Shamanna R; Patel K; Wang W; Jorgensen J; Wang S; Lopez W; Ayala A; Plunkett W; Gandhi V; Kantarjian H; O'Brien S; Keating M; Wierda WG
Leukemia; 2021 Dec; 35(12):3421-3429. PubMed ID: 34007049
[TBL] [Abstract][Full Text] [Related]
37. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study.
Stilgenbauer S; Eichhorst B; Schetelig J; Coutre S; Seymour JF; Munir T; Puvvada SD; Wendtner CM; Roberts AW; Jurczak W; Mulligan SP; Böttcher S; Mobasher M; Zhu M; Desai M; Chyla B; Verdugo M; Enschede SH; Cerri E; Humerickhouse R; Gordon G; Hallek M; Wierda WG
Lancet Oncol; 2016 Jun; 17(6):768-778. PubMed ID: 27178240
[TBL] [Abstract][Full Text] [Related]
38. State-of-the-Art Treatment and Novel Agents in Chronic Lymphocytic Leukemia.
Cramer P; Hallek M; Eichhorst B
Oncol Res Treat; 2016; 39(1-2):25-32. PubMed ID: 26890007
[TBL] [Abstract][Full Text] [Related]
39. Initial treatment of CLL: integrating biology and functional status.
Jain N; O'Brien S
Blood; 2015 Jul; 126(4):463-70. PubMed ID: 26065656
[TBL] [Abstract][Full Text] [Related]
40. Improving treatment for patients with chronic lymphocytic leukemia.
Shanafelt TD
Hematology; 2012 Apr; 17 Suppl 1():S133-6. PubMed ID: 22507801
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]